Anti-Pseudomonas aerosol therapy in cystic fibrosis: Improvement with the new formulation of tobramycin;Aérosolthérapie anti-pyocyanique dans la mucoviscidose: Apport de la tobramycine

Revue de Pneumologie Clinique

Volumn 58, Issue 3, 2002, Pages 131-138

  Foucaud, P ^a   Borel, B ^a   Charara, O ^a   Nathanson, S ^a   Petitprez, P ^a   Pin, I ^b  

^a CENTRE HOSPITALIER DE VERSAILLES   (France)

^b CHU La Tronche and University   (France)

Author keywords

Aerosol delivery; Cystic fibrosis; Pseudomonas aeruginosa; Tobramycin

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM ANTIBIOTIC; CARBENICILLIN; COLISTIN; GENTAMICIN; NEOMYCIN; POLYMYXIN; TOBRAMYCIN; ANTIINFECTIVE AGENT; PENICILLIN DERIVATIVE; PLACEBO;

AEROSOL; ANTIMICROBIAL THERAPY; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TISSUE LEVEL; NEBULIZATION; PSEUDOMONAS AERUGINOSA; RESPIRATORY FUNCTION; RESPIRATORY TRACT INFECTION; REVIEW; ADOLESCENT; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; GRAM NEGATIVE INFECTION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; NEBULIZER; RANDOMIZED CONTROLLED TRIAL; TIME;

ADMINISTRATION, INHALATION; ADOLESCENT; AEROSOLS; ANTIBIOTICS, AMINOGLYCOSIDE; ANTIBIOTICS, PEPTIDE; CARBENICILLIN; CHILD; COLISTIN; COMPARATIVE STUDY; CYSTIC FIBROSIS; DRUG THERAPY, COMBINATION; ENGLISH ABSTRACT; GENTAMICINS; HUMAN; NEBULIZERS AND VAPORIZERS; PENICILLINS; PLACEBOS; POLYMYXIN; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; TOBRAMYCIN; ANTI-BACTERIAL AGENTS; HUMANS; POLYMYXINS;

EID: 0042832221     PISSN: 07618417     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis
2. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: Comparison with activity in serum
3. Inhaled antibiotics in cystic fibrosis
4. Long-term tobramycin aerosol therapy in cystic fibrosis
5. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa
6. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis
7. Nebulised colimycin for early Pseudomonas colonisation in cystic fibrosis
8. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections
9. Use of aerosolized antibiotics in patients with cystic fibrosis
10. Aerosol polymyxin and pneumonia in seriously ill patients
11. Antibiotic prophylaxis in cystic fibrosis: Inhaled cephaloridine as an adjunct to oral cloxacillin
12. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum
13. Efficacy of aerosolized tobramycin in patients with cystic fibrosis
14. Microbiology of airway disease in patients with cystic fibrosis
15. Ventilatory effects of aerosol gentamicin
16. Safety of kanamycin aerosol
17. Inhaled metabisulfite senstivity
18. Preservatives in nebulizer solutions: Risks without benefit
19. Bronchial response to nebulized antibiotics in children with cystic fibrosis
20. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone
21. Hypoxaemia after nebulised salbutamol in wheezy infants: The importance of aerosol acidity
22. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
23. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems
24. Equivalence in TOBI aerosol output from the Pari LC Plus nebuliser using a variety of compressors
25. Nebulizer performance: AFLM study
26. Guidelines for nebulization therapy
27. European Respiratory Society Guidelines on the use of nebulizers
28. Randomised UK/Eire clinical trial of the efficacy and safety of tobramycin 300 mg/5 ml nebuliser solution or nebulized colistin in CF patients
29. Nebulised antipseudomonal antibiotics for cystic fibrosis